Title: Are the Cardiovascular (CV) Risk Reductions Seen with Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional CV Risk Factors?
Abstract: Aims: To estimate the degree to which CV risk reductions demonstrated with empagliflozin in EMPA-REG OUTCOME might be explained by changes in conventional CV factors.
Publication Year: 2017
Publication Date: 2017-10-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot